Patents Examined by Eric J Rogers
  • Patent number: 12221630
    Abstract: The present invention provides a cell culture for obtaining an epithelial organoid, the cell culture comprising i) epithelial stem cells, or tissue fragments comprising said epithelial stem cells, ii) a basal medium for animal or human cells, iii) a Bone Morphogenetic Protein (BMP) inhibitor, iv) a mitogenic growth factor selected from the group consisting of epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), basic fibroblast growth factor (bFGF), brain-derived neurotrophic factor (BDNF) and keratinocyte growth factor (KGF), v) at least one soluble culture enhancer, wherein said at least one culture enhancer induces correct polarization of the cells in said cell culture within the developing organoid such as a laminin/entactin complex or entactin, and vi) a Wnt agonist if said epithelial stem cells, or tissue fragments comprising said epithelial stem cells are healthy cells, wherein said at least one soluble culture enhancer in said cell culture is a laminin/entactin complex in a con
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: February 11, 2025
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: David Joel Agorku, Olaf Thorsten Hardt, Andreas Bosio, Kristin Becker, Dominik Eckardt
  • Patent number: 12215355
    Abstract: Provided herein are methods of producing ? cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: February 4, 2025
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Felicia J. Pagliuca, George Harb, Lillian Ye
  • Patent number: 12215379
    Abstract: In some embodiments described herein are methods performed in situ for analyzing chromatin interaction events in a cell or in cells of a sample such as a non-homogenized tissue sample. The methods can comprise the spatial analysis of chromatin interaction events across cell populations in a biological sample. The methods can further comprise obtaining a biological sample, hybridizing probes to target nucleic acid sequences involved in chromatin interaction events and producing a nucleic acid sequence comprising all or part of the target nucleic acid sequences, amplifying the nucleic acid sequence so produced and detecting the amplified nucleic acid sequence in situ.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: February 4, 2025
    Assignee: 10X GENOMICS, INC.
    Inventors: Patrik Ståhl, Pelin Sahlén
  • Patent number: 12195761
    Abstract: The disclosure provides 3D bioprinted test beds and methods of making the 3D bioprinted teste beds, methods of using the 3D bioprinted test beds for testing and/or comparatively testing two or more test compounds on cell growth and/or behavior, as well as biocompatible methacrylated hyaluronic acid-based bioinks for printing the 3D test beds and/or other articles. The 3D test beds and bioinks include a hydrogel material/precursor and can include extracellular matrix components.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: January 14, 2025
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Christine E. Schmidt, Benjamin Scott Spearman, Tran Ngo
  • Patent number: 12161676
    Abstract: Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic ?-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D ?-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: December 10, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Clive Svendsen, Dhruv Sareen
  • Patent number: 12161762
    Abstract: The present invention relates to a nanohelix-substrate complex for controlling adhesion and polarization of macrophages, a manufacturing method thereof, and a method of controlling adhesion and polarization of macrophages by using the nanohelix-substrate complex, and the method of controlling adhesion and polarization of macrophages may temporally and reversibly control adhesion and phenotypic polarization of macrophages in vivo and ex vivo by controlling application/non-application of a magnetic field to the nanohelix-substrate complex.
    Type: Grant
    Filed: May 30, 2023
    Date of Patent: December 10, 2024
    Assignee: Korea University Research and Business Foundation
    Inventors: Young-Keun Kim, Heemin Kang, Min-Jun Ko, Gunhyu Bae
  • Patent number: 12144827
    Abstract: The present disclosure relates to polynucleotides encoding a chimeric polypeptide comprising a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. Also provided are cells (e.g., T cells) expressing CARs comprising a ROR1-binding protein and overexpressing a c-Jun polypeptide. Overexpression of c-Jun in CAR T cells confers improved properties, e.g., reducing or preventing exhaustion.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: November 19, 2024
    Assignee: Lyell Immunopharma, Inc.
    Inventors: Spencer Park, Queenie Vong, Blythe Sather, Byoung Ryu, Marc Lajoie, Howell Moffett, Brian Weitzner, Yun Song, Scott Boyken, Neeraj Sharma, Shobha Potluri, Bijan Boldajipour
  • Patent number: 12139725
    Abstract: Provided is a composition capable of promoting osteogenic differentiation of stem cells, comprising, as active ingredients, a bone and cartilage progenitor cell culture solution and a multilayer graphene film, which promotes the differentiation of stem cells into specific cells, and thus is expected to be variously applicable in the in vivo/in vitro stem cell application fields.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: November 12, 2024
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, BIOGRAPHENE INC.
    Inventors: Jeong Mook Lim, Ji Yeon Ahn, Jong Bo Park, Byung Hee Hong, Woo Sub Yang
  • Patent number: 12138352
    Abstract: The present invention relates to a nanohelix-substrate complex for controlling adhesion and polarization of macrophages, a manufacturing method thereof, and a method of controlling adhesion and polarization of macrophages by using the nanohelix-substrate complex, and the method of controlling adhesion and polarization of macrophages may temporally and reversibly control adhesion and phenotypic polarization of macrophages in vivo and ex vivo by controlling application/non-application of a magnetic field to the nanohelix-substrate complex.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: November 12, 2024
    Assignee: Korea University Research and Business Foundation
    Inventors: Young-Keun Kim, Heemin Kang, Min-Jun Ko, Gunhyu Bae
  • Patent number: 12084674
    Abstract: Disclosed are nucleic acid sequences comprising a modified HIV Gag sequence, wherein the modified HIV Gag sequence comprises, from 5? to 3?, a matrix domain (MA), capsid (CA) domain, SP1 region, nucleocapsid (NC) domain, SP2 region, and p6 domain, wherein the modified HIV Gag sequence further comprises an exogenous sequence of interest between the NC domain and the SP2 region. Disclosed are methods of producing a recombinant lentivirus comprising transfecting a cell with a plasmid comprising the nucleic acid sequence of one or more of the disclosed nucleic acid sequences in combination with an envelope plasmid. Disclosed are methods of monitoring lentivirus assembly, budding, and/or maturation comprising transfecting a cell with a plasmid comprising any one of the disclosed nucleic acid sequences in combination with an envelope plasmid, wherein the exogenous sequence of interest encodes a detection agent.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: September 10, 2024
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Saveez Saffarian, Mourad Bendjennat
  • Patent number: 12054740
    Abstract: The invention discloses a method for inhibiting the growth of cancer cells by use of an anti-cancer composition containing a conditioned cell culture medium from mesenchymal stem cells and cytokines. It comprises the steps of applying a composition with a conditioned cell culture medium from stem cells and at least one cytokine to cancer cells for growth inhibition of the cancer cells. The cell culture medium can be conditioned with Wharton's Jelly mesenchymal stem cells (WJMSCs) as an WJMSCs-conditioned cell culture medium, and the at least one cytokine is selected from a group consisting of bone morphogenetic protein-4, Dickkopf-related protein, Interferon-? and tumor necrosis factor-related apoptosis-inducing ligand.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: August 6, 2024
    Assignee: Growgene Biotech, Inc.
    Inventors: Pei-Chuan Chuang, Chin-Jing Huang
  • Patent number: 12052986
    Abstract: The present disclosure includes a system to preserve tissue and associated methods. The system can include a portable oxygen source to provide oxygen and apply a pressure gradient to a flow of the oxygen, an organ preservation system having an inlet to fluidly couple to vasculature of the tissue, and an oxygen line to fluidly couple the portable oxygen source to the organ preservation system at the inlet, wherein the portable oxygen source is to apply the pressure gradient to pump fluid containing the oxygen through the organ preservation system.
    Type: Grant
    Filed: July 8, 2021
    Date of Patent: August 6, 2024
    Assignee: Vascular Perfusion Solutions, Inc.
    Inventor: Israel Jessop
  • Patent number: 12049570
    Abstract: The present disclosure relates to the composition and process for the production of an ultra-strong, biocompatible, electroconductive, and stretchable hydrogel, which comprises: a step (a) of physical or chemical modification of natural polymers e.g., preparation of silk nanofiber and double methacrylation of gelatin; a step (b) of graphene oxide (GO) carboxylation; a step (c) of carbodiimidation between methacrylated natural polymers of step (a) and carboxylated GO of step (b); and a step (d) of three dimensional (3D) bioprinting of step (c) with/without silk nanofiber. It was found that these steps in this disclosure give rise to a biocompatible hydrogel with high mechanical strength in the range of load-bearing soft tissue such as tendon and heart as opposed to conventional hydrogels.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: July 30, 2024
    Assignee: INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITY
    Inventors: Chan Hum Park, Young Jin Lee, Olatunji Abolarin Ajiteru, Ok Joo Lee, Ji Seung Lee, Han Na Lee, Md Tipu Sultan, Jang Min Kim, Oh Jun Kwon, Ji Ye Kim, Ji Won Heo, Soon Hee Kim
  • Patent number: 12036243
    Abstract: Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: July 16, 2024
    Assignee: Allogene Therapeutics, Inc.
    Inventors: Regina Junhui Lin, Siler Panowski, Cesar Adolfo Sommer, Thomas John Van Blarcom, Barbra Johnson Sasu, Arun Balakumaran
  • Patent number: 12036257
    Abstract: This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: July 16, 2024
    Assignee: KaliVir Immunotherapeutics, Inc.
    Inventors: Stephen H. Thorne, Daniel J. Byrd, Mingrui Zhang
  • Patent number: 12031158
    Abstract: A method of culturing cells includes placing a cell suspension including i) one of more types of adhesion molecules selected from the group consisting of fragments of laminin molecules, fragments of a basement membrane matrix mixture, and a complete basement membrane matrix mixture and ii) kidney cells on a culture surface of a substrate; and culturing the kidney cells on the substrate to form a confluent monolayer of the cells.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: July 9, 2024
    Assignee: NIKKISO CO., LTD.
    Inventor: Fumihiko Kitagawa
  • Patent number: 12018283
    Abstract: The present invention chiefly aims to provide a process for directly inducing insulin-producing cells from somatic cells without performing artificial gene transfer. The present invention can include a process for producing an insulin-producing cell by inducing differentiation directly from a somatic cell, the process comprising a step of culturing the somatic cell in the presence of a cAMP inducer, and six members selected from the group consisting of a GSK3 inhibitor, a TGF-? inhibitor, a BMP inhibitor, a p53 inhibitor, a PI3K inhibitor, a Notch inhibitor and a RAR agonist, or all members thereof. The insulin-producing cells obtained by the present invention are useful in regenerative medicine and the like.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: June 25, 2024
    Assignees: KATAOKA CORPORATION, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Ping Dai, Yukimasa Takeda, Yoshinori Harada, Junichi Matsumoto, Ayumi Kusaka
  • Patent number: 12018258
    Abstract: Described in this disclosure are CRISPRi systems and methods, along with the related compositions and kits, that combine modularity, stable genomic integration, and ease of transfer to diverse bacteria by conjugation. CRISPRi compositions, methods, systems and kits described herein allow for genetic dissection of bacteria, facilitating analyses of microbiome function, antibiotic resistances and sensitivities, as well as comprehensive screening for host-microbe interactions. Embodiments of the invention comprise compositions, methods, systems, and kits for CRISPRi-based repression of gene expression in bacteria.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 25, 2024
    Assignees: CZ Biohub SF, LLC, The Regents of the University of California
    Inventors: Jason Peters, Carol Gross, Oren Rosenberg, Neha Prasad
  • Patent number: 12012614
    Abstract: The present invention belongs to the field of biomedicine, and relates to an inducer for inducing a mesenchymal stem cell to differentiate into an islet cell. An inducer for inducing a mesenchymal stem cell to differentiate into an islet cell consisted of the following components: GLP-1, parathyroid hormone, paracetamol, rapamycin, icariin, trametinib, EPO and VEGF. Each component in a inducer for inducing a mesenchymal stem cell to differentiate into an islet cell of the present invention is safe and non-toxic, requiring fewer steps and short time to induce differentiation, with high induction efficiency.
    Type: Grant
    Filed: May 25, 2020
    Date of Patent: June 18, 2024
    Assignee: QINGDAO RESTORE BIOTECHNOLOGY CO., LTD.
    Inventors: Bingqiang Zhang, Mengmeng Chen, Cuicui Li, Erpu Wang, Fubin Wang, Wei Zou, Xueqi Fu, Cuijuan Liu
  • Patent number: 11981918
    Abstract: Induced Pluripotent Stem Cell (Ipsc) technology enables the generation and study of living brain tissue relevant to Parkinson's disease (PD) ex vivo. Utilizing cell lines from PD patients presents a powerful discovery system that links cellular phenotypes observed in vitro with real clinical data. Differentiating patient-derived iPSCs towards a dopaminergic (DA) neural fate revealed that these cells exhibit molecular and functional properties of DA neurons in vitro that are observed to significantly degenerate in the substantia nigra of PD patients. Clinical symptoms that drive the generation of other relevant cell types may also yield novel PD-specific phenotypes in vitro that have the potential to lead to new therapeutic avenues for patients with PD.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: May 14, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Alexander Laperle, Samuel Sances, Nur Yucer, Clive N. Svendsen